You are here: Industry Insights > Selvita

News List

Selvita to Present New Data from its Oncology Programs at the Upcoming SITC 2018 b3cnewswire
November 10, 2018
Data presented at the conference will include recent results from Selvita’s discovery phase project targeting cancer immunometabolism – a dual A2A/A2B adenosine receptor antagonist, as well as cancer immunotherapy – a novel class of small molecule direct
Selvita to Present New Data from SEL120 Program at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics b3cnewswire
November 10, 2018
The presentation during the symposium will feature preclinical data from Selvita’s CDK8 inhibitor program SEL120 - potential treatment of acute myeloid and lymphoblastic leukemias. SEL120 is the most advanced, fully-owned oncology program in company’s pip
Selvita Announces Successful Completion of $41 M Book Building b3cnewswire
March 01, 2018
Selvita has received investment declarations implicating placement of all 2,200,000 shares offered in the H series public subscription. The issue price was set at the previously announced maximum limit of PLN 61.00 per share.
Selvita announces first patient dosed in phase I/II clinical trial of SEL24 pharmaasia
April 05, 2017
Selvita announced that the first patient was dosed with SEL24 in a Phase I/II clinical trial, for acute myeloid leukemia (AML).
Selvita Announces First Patient Dosed in Phase I/II Clinical Trial of SEL24 in Acute Myeloid Leukemi b3cnewswire
March 20, 2017
Selvita announced that the first patient was dosed with SEL24 in a Phase I/II clinical trial, for acute myeloid leukemia (AML).
Selvita to Present New Data from its Oncology Programs at the Upcoming AACR Annual Meeting 2017 b3cnewswire
March 14, 2017
Selvita a clinical stage drug discovery and development company focused on innovative medicines for oncology patients, will publish the most recent data from its oncology programs at the upcoming AACR Annual Meeting 2017.